HO-1 and CD39: It Takes Two to Protect the Realm

被引:16
|
作者
Lee, Ghee Rye
Shaefi, Shahzad
Otterbein, Leo E. [1 ]
机构
[1] Harvard Med Sch, Dept Surg, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA
来源
FRONTIERS IN IMMUNOLOGY | 2019年 / 10卷
关键词
heme; innate immunity; adenosine; metabolism; bioenergetics; HEME OXYGENASE-1 EXPRESSION; CARBON-MONOXIDE; EXTRACELLULAR ATP; SERUM BILIRUBIN; BILIVERDIN PROTECTS; INDUCE TOLERANCE; MURINE COLITIS; BILE-PIGMENTS; CELLULAR IRON; TISSUE-INJURY;
D O I
10.3389/fimmu.2019.01765
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cellular protective mechanisms exist to ensure survival of the cells and are a fundamental feature of all cells that is necessary for adapting to changes in the environment. Indeed, evolution has ensured that each cell is equipped with multiple overlapping families of genes that safeguard against pathogens, injury, stress, and dysfunctional metabolic processes. Two of the better-known enzymatic systems, conserved through all species, include the heme oxygenases (HO-1/HO-2), and the ectonucleotidases (CD39/73). Each of these systems generates critical bioactive products that regulate the cellular response to a stressor. Absence of these molecules results in the cell being extremely predisposed to collapse and, in most cases, results in the death of the cell. Recent reports have begun to link these two metabolic pathways, and what were once exclusively stand-alone are now being found to be intimately interrelated and do so through their innate ability to generate bioactive products including adenosine, carbon monoxide, and bilirubin. These simple small molecules elicit profound cellular physiologic responses that impact a number of innate immune responses, and participate in the regulation of inflammation and tissue repair. Collectively these enzymes are linked not only because of the mitochondria being the source of their substrates, but perhaps more importantly, because of the impact of their products on specific cellular responses. This review will provide a synopsis of the current state of the field regarding how these systems are linked and how they are now being leveraged as therapeutic modalities in the clinic.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Central role of Sp1-regulated CD39 in hypoxia/ischemia protection
    Eltzschig, Holger K.
    Koehler, David
    Eckle, Tobias
    Kong, Tianqing
    Robson, Simon C.
    Colgan, Sean P.
    BLOOD, 2009, 113 (01) : 224 - 232
  • [32] CD39/NTPDase-1 expression is associated with activation in T-lymphocytes.
    Pulte, Dianne
    Broekman, Marinas Johan
    Drosopoulos, Joan
    Olson, Kim E.
    Islam, Naziba
    Marcus, Aaron J.
    BLOOD, 2006, 108 (11) : 492A - 492A
  • [33] NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse
    Kauffenstein, Gilles
    Drouin, Annick
    Thorin-Trescases, Nathalie
    Bachelard, Helene
    Robaye, Bernard
    D'Orleans-Juste, Pedro
    Marceau, Francois
    Thorin, Eric
    Sevigny, Jean
    CARDIOVASCULAR RESEARCH, 2010, 85 (01) : 204 - 213
  • [34] The NOTCH1/CD39 axis: a Treg trip-switch for GvHD
    B Del Papa
    A Pierini
    P Sportoletti
    S Baldoni
    D Cecchini
    E Rosati
    E Dorillo
    P Aureli
    T Zei
    R Iacucci Ostini
    L Ruggeri
    A Carotti
    A Velardi
    R Negrin
    M F Martelli
    F Falzetti
    M Di Ianni
    Leukemia, 2016, 30 : 1931 - 1934
  • [35] Loss of vascular expression of nucleoside triphosphate diphosphohydrolase-1/CD39 in hypertension
    Roy, Charlotte
    Tabiasco, Julie
    Caillon, Antoine
    Delneste, Yves
    Merot, Jean
    Favre, Julie
    Guihot, Anne Laure
    Martin, Ludovic
    Nascimento, Daniele C.
    Ryffel, Bernhard
    Robson, Simon C.
    Sevigny, Jean
    Henrion, Daniel
    Kauffenstein, Gilles
    PURINERGIC SIGNALLING, 2018, 14 (01) : 73 - 82
  • [36] The NOTCH1/CD39 axis: a Treg trip-switch for GvHD
    Del Papa, B.
    Pierini, A.
    Sportoletti, P.
    Baldoni, S.
    Cecchini, D.
    Rosati, E.
    Dorillo, E.
    Aureli, P.
    Zei, T.
    Ostini, R. Iacucci
    Ruggeri, L.
    Carotti, A.
    Velardi, A.
    Negrin, R.
    Martelli, M. F.
    Falzetti, F.
    Di Ianni, M.
    LEUKEMIA, 2016, 30 (09) : 1931 - 1934
  • [37] CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker
    Li, Cuicui
    Zhang, Litian
    Jin, Qiqi
    Jiang, Haoyun
    Wu, Chongyang
    BIOMARKERS IN MEDICINE, 2023, 17 (12) : 563 - 576
  • [38] NTPDASE1 (CD39) regulates extracellular nuclecitides-induced vasomotion
    Kauffenstein, G.
    Sevigny, J.
    CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 : 249C - 249C
  • [39] Modulation of Nucleotide Triphosphate Diphosphohydrolase-1 (NTPDase-1)/cd39 in Xenograft Rejection
    Masato Imai
    Ko Takigami
    Olaf Guckelberger
    Keiichi Enjyoji
    R. Neal Smith
    Yuan Lin
    Eva Csizmadia
    Jean Sévigny
    Robert D. Rosenberg
    Fritz H. Bach
    Simon C. Robson
    Molecular Medicine, 1999, 5 : 743 - 752
  • [40] Transmembrane domains confer different substrate specificities and adenosine diphosphate hydrolysis mechanisms on CD39, CD39L1, and chimeras
    Grinthal, A
    Guidotti, G
    BIOCHEMISTRY, 2002, 41 (06) : 1947 - 1956